Balaxi FY26 net profit falls 94% to ₹1.42 crore

Balaxi Pharmaceuticals Limited reported a net profit of ₹1.42 crore for the financial year ended March 31, 2026, a sharp decline of 94.3% compared to ₹25.07 crore in the previous year. Consolidated revenue from operations for the year fell 7.7% to ₹270.17 crore from ₹292.56 crore in FY25. The company attributed the revenue decline to an extended working capital cycle in its institutional business, particularly in Angola, while its Latin America (LATAM) segment delivered strong growth with revenue increasing 11% year-on-year to ₹111.29 crore.

Financial Performance

The Board of Directors approved the audited consolidated financial results for the fourth quarter and financial year ended March 31, 2026. Despite the lower revenues, gross profit margins improved to 44.2% in FY26 from 43.4% in the previous year, reflecting an improved business mix and disciplined product selection. The company’s EBITDA for the year stood at ₹11.35 crore, down 66.1% from ₹33.50 crore in FY25.

Particulars (INR Crore)	FY26	FY25	YoY
Revenue	270.17	292.56	(7.7%)
Gross Profit	119.30	126.86	(6.0%)
Gross Margin %	44.2%	43.4%	+80 bps
EBITDA	11.35	33.50	(66.1%)
Profit After Tax	1.42	25.07	(94.3%)

For the quarter ended March 31, 2026, the company recorded a net profit of ₹0.61 crore, a decrease of 92.9% from ₹8.64 crore in the corresponding quarter of the previous year. Quarterly revenue declined 7.3% to ₹70.71 crore.

Operational Updates

During the year, the company secured 49 new product registrations across Latin America, bringing its total portfolio to 964 registered products. A major milestone was achieved with the receipt of the Manufacturing Licence for the company’s first pharmaceutical formulation facility at Jadcherla, Hyderabad. The facility, focusing on General Oral Solid Dosage (OSD) formulations, is now commissioned and targets demand for high-quality products in Latin American markets. This move supports the company’s transition from an “Asset Light” to an “Asset Right” model, aiming for backward integration and improved profit margins.

Strategic Outlook

Looking ahead, the company remains focused on scaling its institutional business, expanding its product portfolio, and operationalising the new formulation facility. Management has also initiated the process of discontinuing its ancillary Building Hardware business to sharpen its focus on pharmaceuticals and improve working capital efficiency.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.36%	-1.28%	-7.44%	-28.22%	-52.91%	-80.27%

Balaxi Pharmaceuticals Limited has filed its monthly RTA report with the National Stock Exchange of India Limited for the period ended April 2026, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30th January, 2026. The report pertains to the re-lodgement of transfer requests for physical shares under the special window established by the said SEBI circular. The filing was submitted on 12th May, 2026, and signed by Aman Purohit, Company Secretary and Compliance Officer (ICSI Membership No.: A59345).

RTA Report: Physical Share Transfer Re-Lodgements

The report was prepared and submitted by M/s. Aarthi Consultants Private Limited, the Registrar and Share Transfer Agent of Balaxi Pharmaceuticals, bearing SEBI Registration No. INR000000379. Aarthi Consultants, a Category I Registrar and Share Transfer Agent, confirmed the status of re-lodgement requests as of April 2026. The report reflects activity — or the absence thereof — under the special window provided by the SEBI circular dated 30th January, 2026, which governs the re-lodgement of physical share transfer requests.

April 2026 Re-Lodgement Status

The following table summarises the status of physical share transfer re-lodgement requests for the month of April 2026, as reported by Aarthi Consultants Private Limited:

Metric:	Status
No. of requests received during the month:	NIL
No. of requests processed during the month:	NIL
No. of requests approved during the month:	NIL
No. of requests rejected during the month:	NIL
Average time taken for processing of requests (in days):	NA

As confirmed by the RTA, no requests for re-lodgement of physical share transfers were received, processed, approved, or rejected during April 2026. Consequently, the average processing time is reported as not applicable for the period.

Regulatory Compliance and Disclosure

The report has been submitted to the Listing Department of the National Stock Exchange of India Limited in compliance with the applicable SEBI circular. Balaxi Pharmaceuticals has also indicated that the report will be made available on the company's official website at www.balaxipharma.in . The filing was made on behalf of Balaxi Pharmaceuticals by Aman Purohit, Company Secretary and Compliance Officer, and the RTA report was signed by Jagan Mohan Gobburi, Compliance Officer at Aarthi Consultants Private Limited, dated 11th May, 2026.